French pharmaceutical giant Sanofi-Aventis announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Denmarkâs Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily. In addition, the initial results showed that significantly fewer people with type-2 diabetes treated with lixisenatide once-daily, reported hypoglycemic events versus patients treated with exenatide. |
Previous | Home | Next 